A Phase 4, Open-Label, Non-Randomized, Multicenter Study to Evaluate Efficacy (and Safety) of Intravenous Administration of Optison for Contrast-Enhanced Echocardiography in Pediatric Patients.

Pediatr Cardiol · 2026 · PMC13144270 · PMID 40866633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Despite the increase in number of LVWS visualized with Optison to 11.7 ± 0.8 with dose level 1 (p = 0.15) and 11.7 ± 0.8 with dose level 2 (p = 0.15), these changes did not reach statistical significance for this reader.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.